EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence

Hilary Martin iD, Andrew Redfern iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.6846 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Hilary Martin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Breast Neoplasms, Bone Density, Neoplasm Recurrence, Local. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Aromatase inhibitors (AIs) are associated with reduction in bone mineral density (BMD). The use of bone strengthening agents zoledronic acid and denosumab are associated with improved breast cancer outcomes for post‐menopausal patients treated with AIs. This study investigates whether change in BMD with AI therapy is associated with breast cancer recurrence.

Methods

A cohort of patients treated at a single institution diagnosed with hormone receptor‐positive breast cancer with baseline BMD and subsequent BMD test while receiving adjuvant aromatase inhibitor therapy were studied. Demographic, treatment and outcome data was obtained. Simple and multiple linear regression analysis was performed to investigate predictors of annual percent BMD change at the LS and hip. Univariate and multivariate Cox proportional hazards modelling were undertaken to investigate predictors of breast cancer recurrence.

Results

353 patients eligible patients were identified. In multivariate analysis of lumbar spine BMD change, the difference between those in quartile 1, which showed the greatest reduction in BMD, and quartile 3, with substantially less reduction, was significant (HR = 3.02, 95% CI 1.15–7.90 p = 0.025). Hip BMD reduction was also not significantly associated with breast cancer recurrence. The two quartiles with the least reduction in hip BMD showing a non‐significant reduced risk of recurrence relative to the quartile with the greatest ( p = 0.10).

Conclusions

The findings suggest an association may exist between lumbar spine BMD change and breast cancer recurrence for patients treated with adjuvant AI. Further research is required to determine whether BMD change can be utilised as a biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aromatase InhibitorsBreast NeoplasmsBone DensityNeoplasm Recurrence, LocalHumansFemaleMiddle AgedAgedBone Density Conservation AgentsAged, 80 and overAdult

Stichwörter der Autor:innen

bone mineral densitybreast cancer

Substanzen

Aromatase InhibitorsBone Density Conservation Agents

Autor:innen und Institutionen

  • Medical Oncology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
  • School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

ORCID-Profile: Hilary Martin, Andrew Redfern

Zitieren

APA

Martin, H., & Redfern, A. (2024). Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence. Cancer Medicine. https://doi.org/10.1002/cam4.6846

Vancouver

Martin H, Redfern A. Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence. Cancer Medicine. 2024. doi:10.1002/cam4.6846

BibTeX
@article{Martin2024,
  author = {Martin, Hilary and Redfern, Andrew},
  title = {Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6846}
}
Kostenlos starten →